MIRA Pharmaceuticals, Inc. - 10-Q Summary (Q3 2025)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates for neuroscience and metabolic-behavioral disorders. Key assets include Ketamir-2 (oral NMDA-receptor antagonist for neuropathic pain), MIRA-55 (non-psychoactive marijuana analog), and SKNY-1 (acquired preclinical candidate for metabolic modulation). The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(1,137,673) | $(4,459,164) | $(5,452,963) |
| Net Loss Attributable to Common Shareholders | $(22,694,494) | $(26,015,985) | $(5,452,963) |
| Operating Expenses (Total) | $1,316,985 | $4,668,285 | $5,580,527 |
| Cash and Cash Equivalents (End of Period) | $2,641,539 | $2,641,539 | $4,144,560 |
| Total Assets | $7,633,280 | $7,633,280 | $2,923,099 |
| Stockholders' Equity | $7,549,354 | $7,549,354 | $3,573,737 |
| Short-Term Equity Investments | $4,894,366 | $4,894,366 | $0 |
Note: The significant increase in Net Loss Attributable to Common Shareholders in Q3 2025 includes a non-cash "deemed dividend" charge of $21,556,821 related to the SKNY acquisition.
Material Changes vs. Prior Period
- Asset Acquisition: On September 29, 2025, MIRA acquired SKNY Pharmaceuticals, Inc. As partial consideration, the company received 3,521,127 shares of Telomir Pharmaceuticals (TELO) valued at approximately $4.72 million, recorded as short-term equity investments. This significantly increased total assets and equity.
- Operating Expenses: Total operating costs decreased by approximately $912,000 on a YTD basis compared to 2024, primarily due to reduced R&D spend on MIRA-55, despite an increase in stock-based compensation.
- Equity Structure: Common shares outstanding increased from 16.56 million (Dec 31, 2024) to 39.51 million (Sep 30, 2025) due to the issuance of 19.76 million shares to SKNY shareholders and ATM offerings.
- Unrealized Gains: The company recognized an unrealized gain of $176,056 on its short-term TELO investments in Q3 2025, a non-recurring item not present in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. The company expects to continue generating losses and currently lacks sufficient cash to fund operations without additional financing.
- Liquidity Strategy: The company is actively raising capital through its At-The-Market (ATM) equity program. Subsequent to the quarter end (October 2025), the company raised an additional $3.7 million via ATM sales.
- Nasdaq Compliance: The company previously received a deficiency notice regarding minimum stockholders' equity ($2.5M). Following the SKNY acquisition and ATM sales, stockholders' equity rose to $7.55 million, and Nasdaq confirmed compliance on October 7, 2025.
- Clinical Progress:
- Ketamir-2: Phase 1 Single Ascending Dose (SAD) completed with favorable safety; Multiple Ascending Dose (MAD) initiated. Phase 2a for chemotherapy-induced peripheral neuropathy planned for H1 2026.
- MIRA-55: Preclinical data shows analgesic effects without psychoactive side effects; advancing toward IND-enabling studies.
- SKNY-1: Preclinical data supports development for metabolic and behavioral modulation.
- Risks: Reliance on related parties for funding and licensing; failure to obtain regulatory approval; inability to raise additional capital; and potential delisting if equity levels fall again.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $2.64M cash balance against the burn rate of ~$3.5M per nine months and the timeline for future clinical trials.
- Related Party Transactions: Review the terms of the SKNY acquisition and the valuation of the TELO shares received, noting the significant "deemed dividend" accounting impact.
- ATM Utilization: Monitor the remaining capacity under the $75M ATM shelf registration and the pricing of recent share sales.
- Clinical Milestones: Confirm the start date and enrollment progress of the Ketamir-2 Phase 2a trial scheduled for 2026.
- Debt and Liabilities: Note that current liabilities are low ($83,926), but verify any contingent liabilities related to the SKNY license agreement (8% royalty).